Kaken Pharmaceutical Co Ltd (4521):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Kaken Pharmaceutical Co Ltd (4521) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11519
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:20
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:日本
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥27,250見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥54,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥81,750見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Kaken Pharmaceutical Co Ltd (Kaken Pharma) is a pharmaceutical company that conducts research and develops drugs, agrochemicals, medical equipment and animal health products. The company offers solutions in the fields of orthopedics, dermatology, immunology, inflammation, allergies, fungal infection and pain relief. It offers streptomycin and various antifungal agents. Kaken Pharma also offers fungicides, rice herbicide, anti-coccidial for chickens and polypeptide antibiotic. The company conducts research activities in inflammation and immunology, pain relief and fungal infection areas. It operates research laboratories in Kyoto and Shizuoka. Kaken Pharma is headquartered in Tokyo, Japan.

Kaken Pharmaceutical Co Ltd (4521) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Kaken Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Kaken Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Kaken Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Kaken Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Kaken Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Kaken Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Numab Therapeutics Enters into Research and Option Agreement with Kaken Pharma 10
Kyorin Pharma to Enter into Co-Promotion Agreement with Kaken Pharma 11
Kaken Pharma Enters into Distribution Agreement with Dong-A ST 12
Seikagaku Enters Into Co-Marketing Agreement With Kaken Pharma For SI-6603 13
Licensing Agreements 14
Valeant Pharma Enters into Licensing Agreement with Kaken Pharma for KP-470 14
Kaken Pharma Enters into Licensing Agreement with MediWound 15
Brickell Biotech Enters into Licensing Agreement with Kaken Pharma 16
Kaken Pharmaceutical Co Ltd – Key Competitors 17
Kaken Pharmaceutical Co Ltd – Key Employees 18
Kaken Pharmaceutical Co Ltd – Locations And Subsidiaries 19
Head Office 19
Other Locations & Subsidiaries 19
Appendix 20
Methodology 20
About GlobalData 20
Contact Us 20
Disclaimer 20

List of Tables
Kaken Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Kaken Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Kaken Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Kaken Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Kaken Pharmaceutical Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Kaken Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Numab Therapeutics Enters into Research and Option Agreement with Kaken Pharma 10
Kyorin Pharma to Enter into Co-Promotion Agreement with Kaken Pharma 11
Kaken Pharma Enters into Distribution Agreement with Dong-A ST 12
Seikagaku Enters Into Co-Marketing Agreement With Kaken Pharma For SI-6603 13
Valeant Pharma Enters into Licensing Agreement with Kaken Pharma for KP-470 14
Kaken Pharma Enters into Licensing Agreement with MediWound 15
Brickell Biotech Enters into Licensing Agreement with Kaken Pharma 16
Kaken Pharmaceutical Co Ltd, Key Competitors 17
Kaken Pharmaceutical Co Ltd, Key Employees 18
Kaken Pharmaceutical Co Ltd, Subsidiaries 19

List of Figures
Kaken Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Kaken Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Kaken Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Kaken Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Kaken Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Kaken Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Kaken Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Kaken Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Kaken Pharmaceutical Co Ltd (4521):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Integrated Asset Management Corp.:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Integrated Asset Management Cor …
  • Indraprastha Gas Limited (IGL):企業の財務及び戦略的SWOT分析
    Summary Indraprastha Gas Limited (IGL) is a natural gas distribution company that supplies to its customers in the domestic and commercial sectors. The company's products include compressed natural gas and piped natural gas. It provides compressed natural gas for transport; piped natural gas for coo …
  • Oriental Land Co., Ltd. (4661):企業の財務・戦略的SWOT分析
    Oriental Land Co., Ltd. (4661) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • MannKind Corp (MNKD)-医療機器分野:企業M&A・提携分析
    Summary MannKind Corp (MannKind) is a biopharmaceutical company that discovers, develops and commercializes therapeutic products to treat diseases such as diabetes. The company’s lead product, Afrezza is a rapid-acting, inhaled insulin used to control high blood sugar in adults with type 1 and type …
  • Gray Television, Inc.:企業のM&A・提携・投資分析
    Gray Television, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Gray Television, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M …
  • AXA SA:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' AXA SA Mergers and Acquisitions …
  • The Empire District Electric Company:発電所・企業SWOT分析
    The Empire District Electric Company - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information …
  • Quanta Services, Inc. (PWR):企業の財務及び戦略的SWOT分析
    Quanta Services, Inc. (PWR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • MI Bioresearch Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary MI Bioresearch Inc (MI), formerly Molecular Imaging Inc, is a research institute that offers pharmacology research services. The institute offers services such as oncology pharmacology, immuno oncology, in vitro services, imaging and radiation. Its oncology pharmacology include subcutaneous …
  • Pacira Pharmaceuticals Inc (PCRX):製薬・医療:M&Aディール及び事業提携情報
    Summary Pacira Pharmaceuticals Inc (Pacira) discovers, develops, manufactures and commercializes drugs based on its proprietary DepoFoam drug delivery technology. Its lead product candidate, Exparel (bupivacaine liposome injectable suspension) is an amide-type local anesthetic indicated for infiltra …
  • Oversea-Chinese Banking Corporation Limited:企業のM&A・提携・投資分析
    Oversea-Chinese Banking Corporation Limited - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Oversea-Chinese Banking Corporation Limited Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, det …
  • Egalet Corp (EGLT):企業のM&A・提携動向(医療機器分野)
    Summary Egalet Corp (Egalet) formerly BM Research A/S, focuses on the development and commercialization of medicines for patients with moderate to severe pain. Its product portfolio includes OXAYDO tablets for oral use for the management of acute and chronic moderate to severe pain and SPRIX nasal s …
  • MyHeritage, Ltd.:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' MyHeritage, Ltd. Mergers and Ac …
  • Lennox International Inc (LII):企業の財務・戦略的SWOT分析
    Lennox International Inc (LII) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Nevada Gold and Casinos, Incorporated:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Nevada Gold and Casinos, Incorp …
  • IOI Corporation Berhad:企業の戦略・SWOT・財務情報
    IOI Corporation Berhad - Strategy, SWOT and Corporate Finance Report Summary IOI Corporation Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Shanghai Electric Power Co., Ltd. (600021):企業のM&A・提携動向(発電分野)
    Summary Shanghai Electric Power Co., Ltd. (Shanghai Electric Power), a subsidiary of State Power Investment Corporation is an electric energy company that generates and supplies electricity and thermal power. The company generates electricity from coal-fired plants, gas-fired plants, IGCC, gas power …
  • RP Management LLC:製薬・医療:M&Aディール及び事業提携情報
    Summary RP Management LLC (RP Management) is a life sciences financing company that offers biopharmaceutical products. The company’s products include thalomid, myozyme, lexiscan, rituxan, atripla, lyrica, prezista, letairis, januvia, onglyza, neupogen, rotateq, cubicin, savella, and others. It also …
  • Yuke’S Co., Ltd (4334):企業財務及び戦略的SWOT分析
    Summary Yuke'S Co., Ltd (Yuke) is an information technology company that develops and markets gaming applications and products. The company offers WWE, UFC, pro wrestling, fighting and action; and other gaming products. It offers its products in PS3, XBOX360, Wii, DS, PSP, PS2, arcade and other plat …
  • Dilithium Networks, Inc.:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Dilithium Networks, Inc. Merger …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆